CONCORD, MA, 25 April 2025 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2025, taking place in Amsterdam, the Netherlands 7 – 10 May 2025.

“We are excited to share preclinical data on our therapeutic vaccine candidate, CLB-4000, with the Hepatitis B community” said Aileen Rubio, PhD, CEO of ClearB Therapeutics. “Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies. We continue to believe that the functional cure insights translated into the HBsAg variants, CLB-405 and CLB-505, will greatly benefit from the unique adjuvant properties of TQL-1055 and could become an important component of treatment regimens.”